EU confirms suspension of 700 products hit by Indian CRO issues
This article was originally published in Scrip
Around 700 generic drugs will no longer be available in Europe from 21 August after the European Commission issued a decision confirming the products' suspension in light of concerns over data manipulation by the Indian CRO GVK Biosciences.
You may also be interested in...
Dirty data issues continue to plague Indian contract research organizations, denting the reputation of the beleaguered local industry and piling up challenges for marketing authorization holders. The European Medicines Agency (EMA) has now suspended close to 300 products that relied on flawed bioequivalence studies done by the Bengaluru-based Semler Research.
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.